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In the present study, the anti-diabetic effect of aqueous extract of 
Sida rhombifolia ssp. retusa (Malvaceae) leaves was studied in 
normal and streptozotocin (STZ)-induced (60 mg/kg, single 
intraperitoneal injection) diabetic rats. Hypoglycemic activity in 
normal rats was tested after administration of 200 mg/kg of extract.  
Aqueous extract showed a 15% reduction in plasma glucose level 
after 1.5 h of extract administration. When tested in STZ-induced 
diabetic rats the reduction in plasma glucose was 17%. In oral 
glucose tolerance test in normal rats and STZ-induced rats the 
decrease in AUC was 15 and 7% respectively. Glibenclamide was 
used as reference drug and showed significant hypoglycemic effects 
in normal rats but had marginal activity in STZ-induced diabetic rats. 
In hypolipidemic study a dose of 200 mg/kg of aqueous extract has 
shown reduction in triglycerides (TG) (16%), cholesterol (4%), and 
glucose level (10%). Fenofibrate was used as standard drug for 
hypolipidemic study.  
The results obtained from the experiment provided scientific 
evidence in favor of the traditional use of Sida rhombifolia ssp. 
retusa leaves for the treatment of diabetes mellitus. 
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Introduction  
Diabetes mellitus is a metabolic disorder 
characterized by hyperglycemia and disturbances 
of carbohydrate, protein, and fat metabolisms or 
relative lack of the hormone insulin [1]. This 
metabolic disorder affecting approximately 4% of 
the population worldwide and is expected to 
increase by 5.4% in 2025 [2]. The disease 
becomes a real problem of public health in 
developing countries, where its prevalence is 
increasing steadily and adequate treatment is often 
expensive or unavailable [3]. Currently available 
oral anti-diabetic drugs that are used clinically for 
glycemic control include ulfonylureas, 
meglitinides, biguanides, α-glucosidase inhibitors, 
and thiazolidinediones (TZDs) [4]. Each class of 
drug carries the burden of drug-associated side 
effects [5]. All oral anti-diabetic drugs therapies 
have limited efficacy, and mechanism based side 
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effects [6]. However, medicinal herbs are expected 
to have a similar degree of efficacy without the 
side effects associated with conventional drug 
treatment.  
 
Presently, there is growing interest in herbal 
remedies due to the side effects associated with 
the oral synthetic hypoglycemic agents for the 
treatment of diabetes mellitus [2]. Herbal 
medicines have been long used for the treatment 
of diabetic patients and continue to be accepted as 
an alternative therapy.  There are more than 1000 
anti-diabetic plants have been described in the 
scientific literature [7]. The plant kingdom is a 
wide field to search for a natural effective oral 
hypoglycemic or hypolipidemic agent that has 
slight or no side effects. Natural products with 
both hypoglycemic and hypolipidemic properties 
are useful anti-diabetic agents [8]. Sida 
rhombifolia L. ssp. retusa (L.) (Malvaceae) is 
distributed throughout the warmer parts of India, 
known as Bala in Sanskrit and widely used in 
Ayurveda in the treatment of fever and as a 
diuretic [9]. Renowned Ayurvedic physician 
Charaka has categorized bala as brmhaniya (a 
bulk- promoting herb), as balya (tonic), and 
prajasthapana that promote reproduction [10]. 
Several medicinal plants have been extensively 
used in Indian system of medicine (Ayurveda) for 
the management of different types of diabetes. 
Literature survey finds that Sida retusa has been 
used as an antioxidant and hepatoprotective [11], 
in rheumatoid arthritis and in neurological 
complaints including epilepsy [12]. Therefore, the 
search for safe and more effective agents of herbal 
origin has continued to be an important area of 
active research. It is also reported that Sida retusa 
extract is traditionally used by diabetic patients to 
lower their blood glucose levels [13]. This study 
was taken to make a conclusive correlation 
between Ayurvedic claims for this plant and 
consequent scientific studies. 
 
This study investigated the hypoglycemic and 
hypolipidemic effects of aqueous extract of Sida 
rhombifolia ssp. retusa leaves in normal, and 
streptozotocin (STZ)-induced diabetic rats. 
 
Material and Methods 
Collection of Plant Material             
Sida retusa plant was collected from the Academy 
of Development Sciences, Kashale Post Karjat, 
Maharashtra during August, 2006. The sample 
was authentified from Botanical Survey of India, 
and voucher specimen was deposited in our 
Department of Pharmacognosy. The leaves were 
air dried under shade, and powdered to 40 mesh 
for preparation of aqueous extract. 
 
Preparation of Aqueous Extract 
The leaves were crushed in an iron mortar. 
Crushed material was subjected to extraction by 
hot maceration at 60–70°C for 6h continuously in 
distilled water three times. The extract was 
filtered, combined, and evaporated to dryness. 
Dried extract was obtained by concentrating 




Fenofibrate, Glibenclamide, Streptozotocin, and 
biochemicals used in this experiment were 
purchased from Sigma, St. Louis, MO, USA. All 
other chemicals were of analytical grade. 
 
Experimental Animals 
Wistar rats were used at the age of 8 weeks and 
Swiss albino mice were used at the age of 7 
weeks. Rats and mice were assigned in different 
groups (n = 6). Rats and mice were housed under 
conventional conditions with controlled 
temperature, humidity, and lighting (22 ± 2°C, 55 
± 5%, and a 12 h light/dark cycle), and provided 
with a pellet diet and water ad libitum. All 
procedures were conducted according to the 
institutional animal ethics committee. 
 
Induction of Experimental Diabetes 
Diabetes was induced in rats by a single 
intraperitoneal injection of freshly prepared 
streptozotocin (60 mg/kg body weight) in citrate 
buffer (pH = 7.4). Forty-eight hours after STZ-
administration, blood glucose level of each rat was 
determined. Rats with a blood glucose range of 
220–300 mg/100 ml were considered diabetic and 
included in the study.  
 
 




In the experiment, normal rats and STZ-induced 
diabetic rats were used. The rats were divided into 
different groups of six rats each. 
Group 1: Normal control untreated rats received 
0.5% CMC. 
Group 2: Normal rats administered aqueous 
extract of Sida retusa orally (200 mg/kg body 
weight) in distilled water. 
Group 3: Normal rats given glibenclamide orally 
(10 mg/kg body weight) in distilled water.  
Group 4: Diabetic Control with STZ-treated. 
Groups 5 and 6: STZ-treated diabetic rats 
administered aqueous extract of Sida retusa orally 
(200 and 300 mg/kg body weight) in distilled 
water. 
Group 7: STZ-treated diabetic rats given 
glibenclamide orally (10 mg/kg body weight) in 
distilled water.  
For Hypolipidemic study fenofibrate (100 mg/kg) 
in Swiss albino mice was used as standard drug. 
 
Hypoglycemic Study 
Blood was obtained from the retro-orbital 
puncture of all Wistar rats using capillary tubes. 
Blood was collected at 0, 30, 60, 90, 120, 180 min 
in potassium oxalate and sodium fluoride 
containing tubes for plasma glucose measurement. 
Blood samples were centrifuged at 4000 rpm for 
15 min at 4°C. Plasma was separated for the 
estimation of plasma glucose level. 
 
Hypolipidemic Study 
Swiss albino mice were grouped based on their 
plasma triglyceride levels and were dosed orally 
for 14 days. On day 14th animals were bled one 
hour after dosing and plasma was separated for 











Oral Glucose Tolerance Test (OGTT) 
Animals were fasted for 18 h and were grouped 
based on their blood glucose levels. The drugs 
were administered 1 h before glucose load (2 
g/kg). Blood samples were collected at 0, 30, 60, 
90, 120, and 180 min from the reteroorbital sinus 
in heparinised tubes.  Samples were centrifuged at 
4000 rpm for 15 min to separate plasma, for the 
measurement of plasma glucose. 
 
Biochemical Analysis 
Plasma glucose, triglycerides, and cholesterol 
were measured with the help of commercial point 
scientific kits (Ranbaxy Laboratories, India). 
 
Statistical Analysis 
Statistical analysis was performed using one way 
analysis of variance (ANOVA) followed by 
Duncan’s Multiple Range Test (DMRT). Results 
were expressed as mean ± S.D. from six rats in 




Hypoglycemic Effect in Normal and STZ Rats 
The results of the present studies indicate that Sida 
retusa was found to reduce the glucose level in 
normal and the animals made diabetic with STZ. 
Glucose level was assessed in normal rats at 
various time intervals. In normal rats, extract at 
dose of 200 mg/kg showed 14.7% reduction in 
plasma glucose levels after 90 min of oral 
administration. Glibenclamide used as reference 
drug has shown significant 36.6% reduction in 















Table 1. Effect of aqueous extract of Sida retusa on plasma glucose concentration in normal and streptozotocin-
induced (60 mg/kg) diabetic rats. 
Treatment and Dose Plasma glucose concentration (mg%) Time (min) 
Normal rats 0 30 60 90 120 180    
Control (0.5% CMC) 88.4 ± 9.4 94.5 ± 10.4 95.2 ± 9.4 98.7 ± 7.6 100.5 ± 8.3 96.3 ± 7.3 
Extract (200 mg/kg) 86.4 ± 1.6 82.8 ± 2.7 75.2 ± 2.7 71.8 ± 2.2 72.2 ± 1.9 76.2 ± 4.2 
Glibenclamide (10 
mg/kg) 
90.3 ± 4.8 77.8 ± 4.8 69.7 ± 4.5 57.3 ± 4.9 55.5 ± 3.7 53.7 ± 4.0 
Diabetic rats       
Control 292.6 ± 6.5 317.0 ± 9.5 288.0 ± 17.3 295.0 ± 21.6 276.0 ± 18.5 276.2 ± 20.7 
Extract (200 mg/kg) 303.0 ± 4.6 307.0 ± 44.1 270.8 ± 26.4 246.8 ± 23.8 253.6 ± 24.9 252.8 ± 24.7 
Extract (300 mg/kg) 
 
297.0 ± 8.5 303.6 ± 22.4 269.3 ± 16.5 243.6 ± 25.5 260.3 ± 19.3 251.9 ± 21.4 
Glibenclamide  295.6 ± 4.3 275.4 ± 23.9 255.0 ± 23.6 247.8 ± 23.8 251.6 ± 22.4 259.0 ± 19.5 
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STZ-induced rats, the decrease in plasma glucose 
was 16.9 and 16.1% at 90 min with extract at a 
concentration of 200 and 300 mg/kg respectively 
and with glibenclamide it was 16.44% at same 90 
min time point (Table 1). 
 
Oral Glucose Tolerance Test (OGTT) in 
Normal and STZ Rats 
In normal rats, extract (200 mg/kg) has shown 
14.21% reduction in total AUC when compared 
with normal control (0.5% CMC) treated animals. 
The peak increase in mean plasma glucose at 30 
min was 190 mg/dl with normal control group 
animals and it was only 151 mg/dl with extract 
treated animals at a dose of 200 mg/kg. 
Glibenclamide treated animals has shown only 
100 mg/dl plasma glucose at peak and reduction in 
total AUC was 40.86% (Table 2). 
Table 2. Effect of aqueous extract of Sida retusa in 
normal and diabetic induced rats on oral glucose 
tolerance. 
 
In STZ-induced rats, extract (200 mg/kg) has 
shown 7.95% reduction in total AUC (60393 ± 
2686) when compared with diabetic control (0.5% 
CMC) treated animals. The peak increase in mean 
plasma glucose at 30 min was 435 mg/dl with 
control group animals and it was 401 mg/dl with 
extract treated animals. Glibenclamide treated 
animals has shown only 359 mg/dl plasma glucose 
at peak and reduction in total AUC (56376 ± 
1465) was 14.07%. The normal (citrate buffer 
injected) rats have 71% (19008 ± 727) vs. 65606 ± 
2571) less total AUC compared to STZ animals 
(Table 2).  
 
Hypolipidemic Activity in Swiss Albino Mice 
Extract has shown 14.4% reduction in plasma 
tryglyceride compared to control (84.20 mg/dl, 
control and 70.40 mg/dl, extract). Fenofibrate 
showed significant (p<0.05) reduction in plasma 
tryglyceride level. There was no effect on the 
plasma cholesterol levels in both extract as well as 
in fenofibrate. Extract has also 13% reduction in 
plasma glucose levels. Fenofibrate has no effect 
on plasma glucose levels (Table 3). 
Table 3. Effect of aqueous extract of Sida retusa on 






























It is reported that Sida rhombifolia ssp. retusa 
extract have been used traditionally by diabetic 
patients to lower their blood glucose levels. Here, 
we screened leaves extract of this plant in diabetic 
induced and normal rats for its hypoglycemic 
activity. Streptozotocin-induced hyperglycaemic 
has been described as a useful experimental model 
to study the activity of hypoglycaemic agents [14]. 
Treatment 
and Dose 
Blood glucose level (mg/dl) 
Time (min) 
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Streptozotocin selectively destroys the pancreatic 
insulin secreting β-cells, leaving less active cells 
and resulting in a diabetic state [15]. We found 
small reduction in plasma glucose in normal rats 
even after 2 h of dosing, but glibenclamide 
significantly reduced plasma glucose levels. When 
tested in STZ rat model extract has shown nearly 
same reduction in plasma glucose levels as in 
normal rats. Glibenclamide showed only little 
decrease in plasma glucose levels. In oral glucose 
tolerance test (OGTT) in normal rats, we found 
both decrease in peak plasma glucose and in total 
AUC but it was not significant. In STZ-induced 
diabetic rats, we performed the OGTT after 5 days 
of injection. There was significant (p<0.001) 
difference in total AUC between the normal 
(citrate buffer), and STZ injected rats. This is due 
to destruction of pancreas; hence STZ rats were 
not able to release insulin in response to glucose. 
Extract has reduced both peak plasma glucose and 
total AUC. Glibenclamide, a potent hypoglycemic 
agent has showed significant decrease in AUC in 
OGTT in normal rats but has only marginal effect 
in OGTT in STZ rats.  
As diabetes is also associated with 
hypertriglycerides, dyslipidemia, and high levels 
of free fatty acids. A higher level of triglycerides, 
and free fatty acids also causes insulin resistance 
by inhibiting insulin signaling which further 
worsen the situation. Here we tested 
hypolipidemic activity in Swiss albino mice, as 
this is reported to have mild hypertriglyceridemia 
and had been used by many authors for testing 
hypolipidemiac activity. Here we found decrease 
in plasma triglycerides after 14 days of treatment. 
But extract has no effect on plasma cholesterol 
levels. We found some reduction in plasma 
glucose levels also. Fenofibrate used as a 
reference drug has significantly reduced plasma 
triglyceride levels but has no effect on plasma 
cholesterol and glucose levels.  The decrease in 
triglyceride level proves mild hypolipidemic 
activity of the extract and decrease in plasma 
glucose confirms its hypoglycemic activity. 
Glibenclamide treatment was not as effective in 
reducing blood glucose in STZ-diabetic rats as in 
normoglycaemic rats. It has been reported that 
glibenclamide was not effective when destruction 
of β-cells has occurred and hence more effective 
in moderate diabetic rats than in severe diabetic 
animals [16]. The acute hypoglycaemic effect of 
glibenclamide results has been shown from the 
stimulation of insulin release from the residual β-
cells and inhibition of glucagon secretion. As 
reported glibenclamide do not have effect in STZ 
rats but metformin has effect in this model. This 
effect is due to inhibition of hepatic 
gluconeogenesis. We have also seen the same 
thing here. Glibenclamide showed significant 
hypoglycemic effect per se and also reduced 
glucose excursion in OGTT in normal rats. But in 
STZ-induced diabetic rats glibenclamide has very 
marginal activity.  This might be due to 
insufficient pancreas left because of toxicity 
caused by STZ, so there is no sufficient release of 
insulin to cause further reduction in plasma 
glucose. 
Extract has shown mild hypoglycemic activity.  
The mechanism of glucose reduction is either due 
to increased insulin release in response to glucose 
load, peripheral glucose consumption, and 
inhibition of intestinal or renal glucose absorption 
or inhibition of endogenous glucose production. 
Inhibition of hepatic gluconeogenesis could be a 
factor as in OGTT both normal and STZ-induced 
rats were on fasting and fasting causes more 
hepatic gluconeogenesis. As extract has shown 
similar activity in both normal and STZ rats so 
stimulation of peripheral blood glucose utilization 
and inhibition of endogenous glucose production 
appears to be most probable mechanism for its 
action. Due to its effect on triglyceride levels this 
extract could be more effective in type II diabetes, 
where diabetes is associated with abnormal lipid 
profile. We have tested acute dosing of the extract 
in normal and STZ rats. Chronic dosing of this in 
another type II diabetic model could be more 
useful as in Swiss albino mice we got more than 
10% reduction in plasma glucose after 2 weeks of 
dosing. 
In conclusion, Sida rhombifolia ssp. retusa leaves 
extract has shown mild hypoglycemic and 
hypolipidemic activity. Mechanism for 
hypoglycemic activity could be due to peripheral 
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blood glucose utilization, and inhibition of 
endogenous glucose production. The investigation 
provides biochemical evidence to validate the use 
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